Self sufficiency in growth and cell division
Protooncogenes - genes in normal cells which encode proteins that have normal function in cells. Protooncogenes are physiologic regulators of cell proliferation and differentiation
Oncogenes - genes that promote autonomous cell growth in cancer cells. Oncogenes are characterized by the ability to promote cell growth in the absence of normal mitogenic signals
Oncogene products, called oncoproteins, resemble the normal products of protooncogenes with the exception that oncoproteins are devoid of important regulatory elements
Functional Category of Oncogenes
1) Growth Factors - neoplastic cells acquiries the ability to synthesize the same growth factors to which they are responsive. eg platelet-derived growth factor (PDGF) and transforming growth factor α (TGF-α)
2) Growth Factor Receptors - Mutations and pathologic over expression of normal forms of growth factor. Mutant receptors give signals to the cell evenb in absecence of growth factors. Eg EGF – epidermal growth factor overexpressed in 80% of squamous cell carcinoma of lung. HER2 is amplified in 25% to 30% of breast cancers and adenocarcinomas of the lung, ovary, and salivary glands.
3)Proteins Involved in Signal Transduction - RAS and ABL
RAS – gets activated by exchanging GDP for GTP. RAS when activated induce signal to nucleus for cell prolifration by inducing mitogenic cascade. RAS is short lived, GTPase inactivate GTP there by deactivates RAS but in mutant RAS protein GTPase activity fails to be augmented. – uncontrlooed cell proliferation.
ABL - ABL protooncogene has tyrosine kinase activity. In chronic myeloid leukemia and certain acute leukemias, the ABL gene is translocated from its normal abode on chromosome 9 to chromosome 22, where it fuses with part of the breakpoint cluster region (BCR) gene. The BCR-ABL hybrid gene has potent tyrosine kinase activity and it activates several growth stimulating pathways.
4) Nuclear Regulatory Proteins - Growth autonomy may occur as a consequence of mutations affecting genes that regulate transcription of DNA. A host of oncoproteins, including products of the MYC, MYB, JUN, FOS, and REL oncogenes, localised on the nucleus and there mutant varitey may lead to sustained proliferation of cells.
5) Cell-Cycle Regulators – cyclin, CDK and CDK inhibitors
Designer drugs- why do we need to know about the growth signalling pathway
Cetuximab: antibody against EGFR
Imatinib mesylate: inhibitor of Abr-bcl chimeric protein which acts as a tyrosine kinase; DOC in CML
Gefitinib, Erlotinib: inhibitor of EGFR tyrosine kinase activity
Bevacizumab: antibody against VEGF
Rituximab: CD20 antibody, used in B cell NHL
Gemtuzumab: CD33 antibody, used in AML
Alemtuzumab: CD52 antibody, used in CLL
IFNα used in leukemia, melanoma to increase the tumor immunity
Trastuzumab/ Herceptin: Ab against ERB B2/ HER/ Neu growth factor receptors on breast cancer cells
Insensitivity to Growth-Inhibitory Signals
Implies mutation in tumor suppressor genes
Unlike oncogenes, the tumor suppressor genes are recessive, so both the genes should be mutated( Knudson’s two hit hypothesis)
Main examples are
RB gene causing Retinoblastoma
TP53 gene mutation causing many cancers
APC gene mutation causing Adenomatous Polyposis Coli, and finally colon cancer
Pathogenesis of Retinoblastoma;
Note the Knudson’s two hit hypothesis
p53 Gene: Guardian of the Genome
p53 is the central monitor of stress in the cell and can be activated by anoxia, inappropriate oncogene signaling, or DNA damage. Activated p53 controls the expression and activity of genes involved in cell cycle arrest, DNA repair, cellular senescence, and apoptosis
If DNA damage cannot be repaired, p53 induces cellular senescence or apoptosis. Of human tumors, 70% have homozygous loss of p53. Patients with the rare Li-Fraumeni syndrome inherit one defective copy
Apoptosis : There is activation of a proteolytic cascade of caspases that destroys the balance between pro-apoptotic (e.g., BAX, BAK) and anti-apoptotic molecules (BCL2, BCL-XL)
p53 can be incapacitated by binding to proteins encoded by oncogenic DNA viruses like HPV, and possibly EBV and HBV
Telomerase and limitless replicative potential of cancer cell
In normal cells, which lack expression of telomerase, the shortened telomeres generated by cell division eventually activate cell cycle checkpoints, leading to senescence and placing a limit on the number of divisions a cell may undergo
Tumor cells reactivate telomerase, thus staving off mitotic catastrophe and achieving immortality.
Function of telomerase in cancer causation
Evasion of Apopotosis
reduced levels of Fas in hepatocellular carcinomas render the tumor cells less susceptible to apoptosis by FasL.
Overexpression of BCL2 protects lymphocytes from apoptosis and allows them to survive for long periods
Some tumors have high levels of FLIP, a protein that can bind death-inducing signaling complex and prevent activation of caspase 8
Certain melanoma cells show loss of APAF-1, blocking the mitochondrial-cytochrome c pathway.
Defective DNA repair
Genomic Instability-Enabler of Malignancy
Hereditary Nonpolyposis Colon Cancer Syndrome
autosomal recessive disorders comprising
Bloom syndrome, ataxia-telangiectasia, and Fanconi anemia
Development of Sustained Angiogenesis
pro-angiogenic cytokines, such as vascular endothelial growth factor (VEGF)
Anti- angiogenic protein produced by VHL gene( Von Hippel Lindau): VHL acts as a tumor suppressor gene, and its is associated with cell cancers, pheochromocytomas, hemangiomas of the CNS and retina (VHL syndrome).
Ability to Invade and Metastasize
Invasion of Extracellular Matrix (ECM)
Detachment of tumor cells from each other
Degradation of ECM
Attachment to novel ECM components
Migration of tumor cells
Vascular Dissemination and Homing of Tumor Cells